Drug Discovery World

MAY 7, 2024

DDW Editor Reece Armstrong speaks to David Chau , Global Bioprocess Application Specialist, Separation and Purification Sciences Division, 3M, about challenges in producing monoclonal antibodies (mAbs) and how single-use technologies can simplify processes. RA: What are some of the current limitations for producing mAbs? He earned his Ph.D

Antibody 59

Antibody Production Manufacturing Engineer 59

The Pharma Data

NOVEMBER 26, 2020

26, 2020 /PRNewswire/ — BASE10 Genetics and DNA Link today announced their collaboration on a research project to evaluate the usability of DNA Link ‘ s AccuFind COVID-19 IgG antibody test in a healthcare setting. Study will expand access to antibody testing outside of laboratory settings. DNA Link, Inc.

DNA 52

DNA Antibody Research Genome 52

BioTech 365

SEPTEMBER 2, 2020

DNA Link’s Serology Test Showed High Degree of Sensitivity and Specificity for Detecting COVID-19 IgG Antibodies CHICAGO–(BUSINESS WIRE)–BASE10 Genetics, Inc.

DNA 40

DNA Antibody Genetics 40

Roots Analysis

DECEMBER 12, 2021

DNA data storage involves encoding and decoding binary data to and from synthesized strands of DNA. DNA data storage is an innovative technology that works by encoding large digital data sequences of binary form (0s and 1s) into DNA sequences (Adenine (A), Guanine (G), Cytosine (C) and Thymine (T)). DNA Storage.

DNA 52

DNA Research Engineer Marketing 52

Roots Analysis

JANUARY 21, 2024

With fourteen approved drugs and several drug candidates being evaluated under different stages of development, antibody drug conjugates (ADCs) are now recognized as a potent class of targeted therapeutics. In this context, the role of the linker molecule and the conjugation technology used is pivotal.

Antibody 40

Antibody Recombinant DNA Technology Drugs Marketing 40

BioTech 365

JULY 28, 2021

Touchlight and Vanderbilt University Medical Center collaborate on DARPA Pandemic Prevention Platform programme to develop synthetic DNA-based antibody to protect against emerging threats Touchlight and Vanderbilt University Medical Center collaborate on DARPA Pandemic Prevention Platform programme to develop synthetic DNA-based … Continue reading (..)

DNA 52

DNA Antibody Development 52

BioTech 365

JUNE 7, 2021

Applied DNA Reports Veterinary COVID-19 Vaccine Candidate Induces Neutralizing Antibodies in 100% of Trial Cohort Against B.1.1.7, 1.526 Variants and Sets August 2021 Mink Challenge Trial Launch Applied DNA Reports Veterinary COVID-19 Vaccine Candidate Induces Neutralizing Antibodies in … Continue reading →

DNA 52

DNA Antibody Trials Vaccination 52

The Pharma Data

SEPTEMBER 11, 2021

Boehringer Ingelheim believes Twist’s ability to generate potent, diverse therapeutic antibodies by mining its comprehensive libraries, combined with our extensive capabilities and experience in drug discovery and development, will enable us to deliver breakthrough opportunities to patients,” said Clive R. Wood, Ph.D., About Twist Biopharma.

Antibody 52

Antibody DNA Containment Manufacturing 52

Drug Discovery World

MARCH 22, 2023

Preventing metastatic progression NETs are web-like DNA structures and are covered with cancer-promoting proteins that are released by activated neutrophils and that have been shown to engulf tumours and promote immune evasion, tumour progression and metastases.

Antibody 52

Antibody Protein DNA Drugs 52

XTalks

SEPTEMBER 30, 2020

The research shows that the activity of the immune messenger type 1 interferon (IFN) protein is diminished, either by genetic mutations or an autoimmune attack by neutralizing antibodies against it, in a subset of COVID-19 patients. These rogue antibodies blocked interferon action and were not present in patients with mild COVID-19 cases.

Antibody 135

Antibody Genetics Research In-Vitro 135

BioTech 365

NOVEMBER 23, 2020

Twist Bioscience Announces Positive Preclinical Data for SARS-CoV-2 Antibodies Twist Bioscience Announces Positive Preclinical Data for SARS-CoV-2 Antibodies SOUTH SAN FRANCISCO, Calif.–(BUSINESS

Antibody 52

Antibody DNA 52

Pharmaceutical Technology

MARCH 28, 2023

GSK’s trial evaluated the programmed death receptor-1 (PD-1)-blocking antibody Jemperli (dostarlimab). According to the National Cancer Institute, mismatch repair cells are “cells that have mutations in certain genes that are involved in correcting mistakes made when DNA is copied in a cell”.

DNA 130

DNA Clinical Trials Clinical Trials Trials 130

BioPharma Reporter

JUNE 24, 2021

Iksuda Therapeutics, a developer of a new generation of antibody drug conjugates (ADCs), has expanded its research collaboration and license agreement with LegoChem Biosciences Inc (LCB).

DNA 64

DNA Licensing Licensing Antibody 64

Drug Discovery World

MAY 25, 2023

DNA Script: SYNTAX DNA printing platform Using the company’s EDS technology, the SYNTAX platform can synthesise up to 96 highly accurate, ready-to-use DNA oligos with maximum lengths of up to 120nt in less than 24 hours in the laboratory.

Production 52

Production Reagent DNA Drugs 52

Pharmaceutical Technology

NOVEMBER 3, 2022

Trial 1092 met the primary endpoint of the percentage of subjects with HBV deoxyribonucleic acid (DNA) levels less than 20 IU/ml following 24 weeks of treatment. At 24 weeks, 21% of the participants who received 25mg Vemlidy attained HBV DNA less than 20IU/ml versus 0% in the placebo arm.

DNA 130

DNA FDA Approval Clinical Trials Clinical Trials 130

Pharmaceutical Technology

JULY 6, 2022

The researchers found evidence that antibodies are linked to an attack on the cells lining the blood vessels in the brain, causing inflammation and damage. The researchers also observed that antibodies produced in response to Covid-19 may wrongly act on cells vital to the blood-brain barrier.

Immune Response 162

Immune Response Antibody Gene DNA 162

Drug Discovery World

OCTOBER 20, 2023

The latest acquisitions and strategic partnerships in the drug discovery and development sector reveal the areas where companies predict significant growth in the near future: proteomics, CAR-T, antibody discovery, artificial intelligence (AI) and microbiomics. We aim to continue to ‘open up’ the druggable antibody space.”

Drugs 52

Drugs Antibody DNA Gene Therapy 52

BioTech 365

SEPTEMBER 2, 2020

(Nasdaq: SRNE, “Sorrento”) and SmartPharm Therapeutics, Inc. (“SmartPharm”) announced today that Sorrento has completed the acquisition of SmartPharm, a gene-encoded protein therapeutics company developing non-viral DNA and … Continue reading →

DNA 40

DNA In-Vivo Protein Gene 40

Drug Discovery Today

SEPTEMBER 16, 2021

Demand for Touchlight’s synthetic DNA vector has grown rapidly since last year.dbDNA™ is driving biomedical innovations such as DNA and mRNA vaccines, synthetic DNA-based neutralising antibody therapies, and more.Touchlight’s synthetic DNA vector is revolutionising genetic medicine manufacture by offering a superior alternative to traditional plasmid (..)

DNA 45

DNA Genetics Antibody Manufacturing 45

Pharmaceutical Technology

JUNE 8, 2023

The partnership’s initial focus is to support drug developers to advance cell and gene therapies (CGT) using pioneering modalities including viral vectors (AAV, LVV, RV and HSV), antibodies (mAb, bsAb and ADC), CAR-T therapies and vaccines (DNA, mRNA and protein).

Gene Therapy 130

Gene Therapy Gene Development Antibody 130

The Pharma Data

DECEMBER 23, 2020

” Dr. Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” mg dose group and 84% demonstrating neutralizing antibodies in the 2.0

DNA 40

DNA Vaccination Vaccine Immune Response 40

Roots Analysis

FEBRUARY 27, 2024

What are Affimers : Affimers are small proteins that target and bind molecules on cellular surfaces in a manner analogous to monoclonal antibodies. Antibody drug conjugates (ADCs) are a class of cancer drugs that combine the targeting specificity of monoclonal antibodies with the cytotoxic potency of small-molecule drugs.

Antibody 52

Antibody Licensing Licensing Contract Manufacturing 52

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

In-Vivo 162

In-Vivo Genome Genomics Gene Editing 162

Pharmaceutical Technology

FEBRUARY 14, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

In-Vivo 130

In-Vivo DNA Antibody Gene 130

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. In terms of application diversity, Eli Lilly is the top company, followed by C.

Genetics 130

Genetics DNA Antibody Genome 130

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. IgG antibody responses are a useful marker of antigen exposure to diagnose immunodeficiency.

Gene Expression 130

Gene Expression Gene Genetic Engineering Antibody 130

Pharmaceutical Technology

FEBRUARY 3, 2023

Since HIV integrates with the DNA, eliminating the virus from the body is very difficult, explains David Montefiori, PhD, director of the Laboratory for AIDS Vaccine Research and Development at Duke University in Durham, North Carolina. The failure of several late-stage trials highlights the challenging nature of HIV vaccine development.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

XTalks

DECEMBER 28, 2023

HDFN is a condition where the mother’s antibodies attack the red blood cells (RBCs) of the fetus or newborn, leading to hemolysis, or rapid destruction of the baby’s RBCs. Nipocalimab is an investigational monoclonal antibody that targets the neonatal Fc receptor.

Trials 97

Trials Clinical Trials Clinical Trials Antibody 97

Pharmaceutical Technology

MAY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Peptides have a longer shelf life due to their simplicity and ease of transport.

Antibody 130

Antibody DNA Production Medicine 130

Pharmaceutical Technology

MARCH 1, 2023

The drug candidate targets DNA-dependent protein kinase (DNA-PK). Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. The drug candidate is administered through the oral route in the form of capsule and tablet. It is a new chemical entity.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

MARCH 1, 2023

The drug candidate targets DNA-dependent protein kinase (DNA-PK). Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. The drug candidate is administered through the oral route in the form of capsule and tablet. It is a new chemical entity.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

FEBRUARY 14, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Antibody 263

Antibody DNA Research Development 263

Pharmaceutical Technology

JUNE 4, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. bluebird bio is also developing drugs based on DNA and retro-virus vectors.

Gene Therapy 246

Gene Therapy DNA Gene Genetics 246

Pharma Packaging Solutions

JUNE 30, 2023

Whole blood, organ and tissue transplants, breast milk, antibodies for passive immunity, fecal microbiota, human reproductive cells, and stem-cell therapy are all examples of this type of biologic.

Recombinant DNA Technology 52

Recombinant DNA Technology Packaging Packaging Gene Therapy 52

Pharmaceutical Technology

FEBRUARY 14, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Antibody 242

Antibody DNA Research Development 242

XTalks

FEBRUARY 14, 2024

This includes first-in-class immunotherapy products such as novel antibodies and CAR T-cell treatments targeting CTLA-4. Previously, he served as CFO of Artios, a UK-based DNA damage response company where he led the company’s $153 million Series C fundraising.

Life Science 119

Life Science DNA Production Clinical Trials 119

Drug Discovery World

JUNE 7, 2023

Hosted by DDW and sponsored by DNA Script, join us for this free-to-attend roundtable to learn about the biggest opportunities for the future of drug discovery and development. Is it true that the next era will belong to antibody drug conjugates? Panellists will discuss the following questions: Where will the opportunities be in 2024?

Development 52

Development Gene Therapy Drugs DNA 52